Crinetics Pharmaceuticals Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to a loss of $0.96 per share a year ago.
Crinetics Pharmaceuticals, Inc. - Special Call
Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medical & Development Officer Isabel Kalofonos - Chief Commercial Officer Tobin Schilke - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Anthea Li - Jefferies LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brian Skorney - Robert W.
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate Participant Dana Pizzuti - Chief Medical & Development Officer Gayathri Diwakar - Head of Investor Relations Isabel Kalofonos - Chief Commercial Officer R.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $0.94 per share a year ago.
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Toby Schilke - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Jessica Fye - JPMorgan Gavin Clark-Gartner - Evercore ISI Francis DiGiovanna - TD Securities Cory Chobenville - LifeSci Capital Catherine Okoukoni - Citizens Alex Thompson - Stifel Maxwell Skor - Morgan Stanley Will Scheibler - Leerink Partners Anthea Theresa Li - Jefferies David Lebowitz - Citi Brian Skorney - Baird Douglas Tsao - H.C. Wainwright Andy Chen - Wolfe Research Catherine Novack - Jones Operator Welcome to the Crinetics Pharmaceuticals First Quarter 2025 Financial Results Conference Call.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago.
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA
Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over injectable somatostatin analogs, achieving high IGF-1 control rates in pretreated patients. Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant in congenital adrenal hyperplasia highlight CRNX's expanding therapeutic potential.
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Isabel Kalofonos - Chief Commercial Officer Dana Pizzuti - Chief Medical and Development Officer Steve Betz - Founder & Chief Scientific Officer Marc Wilson - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Tyler Van Buren - TD Cowen Joe Schwartz - Leerink Partners Jessica Fye - J.P. Morgan Gavin Clark-Gartner - Evercore ISI Catherine Okoukoni - Citizens Dennis Ding - Jefferies Catherine Novack - Jones Trading Rohan Mathur - Oppenheimer Andy Chen - Wolfe Research Charles Moore - Baird Operator Good afternoon, everyone.
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement.
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief Executive Officer Marc Wilson - Chief Financial Officer Dana Pizzuti - Chief Medical and Development Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Cory Jubinville - LifeSci Capital Jessica Fye - J.P. Morgan Jeff Hung - Morgan Stanley Charlie Moore - Baird Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Douglas Tsao - H.C.
Did this congressman benefit from a stock buy just before FDA approval?
On October 3, Representative Josh Gottheimer of New Jersey's 5th district disclosed a September 25 investment in Crinetics Pharmaceuticals (NASDAQ: CRNX), a mid-cap stock that no U.S. politician had previously traded.
